With a dedicated, First-to-File development team, Alvogen has more than 200 products in its pipeline - including solid dose, controlled release and transdermal patch products for the U.S. market. Our product portfolio consists of a broad range of leading molecules that span most therapeutic areas.
Alvogen is rethinking the way generics are brought to market.
From our highly selective R&D strategy to our more rigorous manufacturing standards to our consolidated global supply chain, we're creating more meaningful ways to meet the needs of pharmacies and consumers.
Alvogen is a multinational pharmaceuticals company with commercial operations in over 30 countries. The company is focused on developing, manufacturing and distributing generic, brand and over-the-counter brands with 1,900 employees worldwide. With more than 200 pharmaceutical projects in development and registration, the group’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology.
Alvogen is committed to serving our customers by providing high quality, affordable generic products.
Alvogen is built on the strong foundation of Norwich Pharmaceutical Services, a U.S. company with a 125-year history and an unsurpassed regulatory track record. The Norwich plant, with an annual capacity of five billion tablets and capsules, is Alvogen’s American manufacturing base.
Located in Norwich, New York, with 8 billion unit total capacity, Alvogen’s Norwich, NY manufacturing site has long set the standard for service, quality and innovation.
Our cutting-edge R&D Center, located in Pine Brook, New Jersey, focuses exclusively on the development of First-to-File and Difficult-to-Formulate generics.
Would you like to connect with our Business Development team? Do you have an interesting idea you would like to share with us or would you just like to learn more about our business? We would like to hear from you.
Send a proposal